Bildkälla: Stockfoto

BioInvent Q4 2022: Focusing on Subcutaneous BI-1206 - Redeye

Redeye comments on BioInvent's Q4 report. The most significant development in the period is the initiation of a phase I study with a new subcutaneous version of the main candidate BI-1206, which should be free of some of the side effects of the intravenous version.

Redeye comments on BioInvent's Q4 report. The most significant development in the period is the initiation of a phase I study with a new subcutaneous version of the main candidate BI-1206, which should be free of some of the side effects of the intravenous version.
Börsvärldens nyhetsbrev
ANNONSER